Treatment with ACE inhibitors until the end of life? Cardiovascular- protective blockade of the renin-angiotensin system;ACE-hemmertherapie bis ans lebensende? Kardio- und vaskuloprotektive mechanismen durch blockade des renin-angiotensin-systems

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 27, 2004, Pages 1513-1518

  Werner, N ^a   Bohm M ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INDAPAMIDE; PERINDOPRIL; RAMIPRIL;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE; STROKE;

AGING; ALZHEIMER DISEASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD VESSELS; CARDIOVASCULAR PHYSIOLOGY; CEREBROVASCULAR ACCIDENT; HEART; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIUM; RENIN-ANGIOTENSIN SYSTEM;

EID: 3042714335     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826895     Document Type: Review

References (43)

1. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828
2. Ahmed A, Kiefe CI, Allman RM, Sims RV, DeLong JF. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002; 50: 1659-1666
3. Barnes NM, Cheng CH, Costall B, Naylor RJ, Williams TJ, Wischik CM. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol 1991; 200: 289-292
4. Böhm M, Lippoldt A, Wienen W, Ganten D, Bader M. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin 11 receptor blockade. Mol Cell Biochem 1996; 163-164: 217-221
5. Brilla CG, Reams GP, Maisch B, Weber KT. Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix. Eur Heart J 1993; 14: 57-61(Suppl J
6. Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, Nachev C, Potter J, Sever P, Staessen J, Swift C, Tuomilehto J. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001; 18: 151-164
7. Clarkson PB, Wheeldon NM, MacLeod C, Tennent M, MacDonald TM. Effects of angiotensin II and aldosterone on diastolic function in vivo in normal man. Clin Sci (Lond) 1994; 87: 397-401
8. Dostal DE, Hunt RA, Kule CE, Bhat GJ, Karoor V, McWhinney CD, Baker KM. Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways. J Mol Cell Cardiol 1997; 29: 2893-2902
9. Ford CM, Li S, Pickering JG. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation. Arterioscler Thromb Vasc Biol 1999; 19: 1843-1851
10. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-2052
11. Gabrielsen A, Bie P, Christensen NJ, Frandsen E, Galatius S, Pump B, Sorensen VB, Kastrup J, Norsk P. Systemic vascular resistance during brief withdrawal of angiotensin converting enzyme inhibition in heart failure. Scand J Clin Lab Invest 2002; 62: 245-254
12. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62: 749-756
13. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349: 1493-1497
14. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616
15. Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta): retards A beta aggregation, deposition, fibril formation, and inhibits cytotoxicity. J Biol Chem 2001; 276: 47863-47868
16. Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, McMurdo ME. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart 2002; 88: 373-377
17. Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121: 355-362
18. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361: 1843-1848
19. Libby P, Sukhova G, Lee RT, Liao JK. Molecular biology of atherosclerosis. Int J Cardiol 1997; 62: S23-S29(Suppl 2
20. Linz W, Jessen T, Becker RH, Scholkens BA, Wiemer G. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation 1997; 96: 3164-3172
21. Lucius R, Gallinat S, Busche S, Rosenstiel P, Linger T. Beyond blood pressure: new roles for angiotensin II. Cell Mol Life Sci 1999; 56: 1008-1019
22. Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordin DL, Krumholz HM. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003; 146: 250-257
23. Morisco C, Condorelli M, Crepaldi G, Rizzon P, Zardini P, Villa G, Argenziano L, Trimarco B. Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril. Cardiovasc Drugs Ther 1997; 11: 63-69
24. Nickenig G, Harrison DG.The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002; 105: 393-396
25. Nonoguchi H, Kiyama S, Inoue H, Nakayama Y, Inoue T, Kohda Y, Machida K, Tajima A, Kitamura K, Miyoshi T, Shimada H, Shimada H, Tajiri M, Honda Y, Tanaka M, Tomita K. Angiotensin-converting enzyme inhibitor withdrawal and ACE gene polymorphism. Clin Nephrol 2003; 60: 225-232
26. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res 1991; 68: 1560-1568
27. O'Keeffe S, Harvey G, Lye M. Use of angiotensin-converting enzyme inhibitors in elderly patients with heart failure. Age and Ageing 1998; 27: 297-301
28. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766
29. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapri. The Quinapril Heart Failure Trial Investigators. J Am Coll Cardiol 1993; 22: 1557-1563
30. Piccoli GB, Anania P, Biancone L, Mezza E, Vischi M, Jeantet A, Rabbia C, Savío D, Rossatto D, Gai M, Perin PC, Segoloni GP. Hypertensive rebound after angiotensin converting enzyme inhibitor withdrawal in diabetic patients with chronic renal failure. Nephrol Dial Transplant 2001; 16: 1084-1085
31. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587
32. Pugh KG, Wei JY. Clinical implications of physiological changes in the aging heart. Drugs Aging 2001; 18: 263-276
33. Ratnasabapathy Y, Lawes CM, Anderson CS. The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease. Drugs Aging 2003; 20: 241-251
34. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59: 551-571
35. Schunkert H, Jackson B, Tang SS, Schoen FJ, Smits JF, Apstein CS, Lorell BH. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993; 87: 1328-1339
36. Stephan D, Grima M, Welsch M, Barthelmebs M, Vasmant D, Imbs J. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system. Fundam Clin Pharmacol 1996; 10: 474-483
37. Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003; 26: 609-614
38. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603
39. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
40. Wang ZQ, Moore AF, Ozono R, Siragy HM, Carey RM. Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart. Hypertension 1998; 32: 78-83
41. Wei JY. Age and the cardiovascular system. N Engl J Med 1992; 327: 1735-1739
42. Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, Inagami T. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 2000; 35: 313-318
43. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153